Summary
Intuitive Surgical, Inc. (ISRG) demonstrated robust financial performance in the third quarter and first nine months of 2010, reflecting strong demand for its da Vinci Surgical Systems. Total revenue grew significantly year-over-year, driven by increased sales of both systems and recurring revenue from instruments, accessories, and service contracts. The company's strategic focus on enhancing the da Vinci platform with new models like the da Vinci Si and Si-e, coupled with positive procedural adoption, particularly in gynecology and urology, contributed to this growth. Despite increased operating expenses related to expansion and stock-based compensation, the company maintained healthy operating margins and reported substantial net income growth. Financially, ISRG boasts a strong balance sheet with a significant increase in cash and investments, bolstered by positive operating cash flows. The company also continued its share repurchase program. Looking ahead, management anticipates continued investment in research and development and expects ongoing growth, though it also acknowledges potential impacts from healthcare policy changes, including the Affordable Care Act and associated excise taxes on medical devices.
Financial Highlights
46 data points| Revenue | $344.40M |
| Cost of Revenue | $93.80M |
| Gross Profit | $250.60M |
| R&D Expenses | $26.90M |
| SG&A Expenses | $91.60M |
| Operating Expenses | $118.50M |
| Operating Income | $132.10M |
| Net Income | $86.60M |
| EPS (Basic) | $0.24 |
| EPS (Diluted) | $0.24 |
| Shares Outstanding (Basic) | 354.60M |
| Shares Outstanding (Diluted) | 364.50M |
Key Highlights
- 1Total revenue increased by 23% to $344.4 million for Q3 2010 compared to $280.1 million in Q3 2009.
- 2Net income grew by 34% to $86.6 million for Q3 2010, up from $64.5 million in Q3 2009.
- 3The installed base of da Vinci Surgical Systems grew to 1,661 by September 30, 2010, up from 1,308 a year prior.
- 4Recurring revenue (instruments, accessories, and service) increased by 28% to $184.8 million in Q3 2010.
- 5The da Vinci Si Surgical System accounted for 86% of system sales in Q3 2010, demonstrating strong market acceptance of the newer model.
- 6Operating cash flow for the first nine months of 2010 was $404.1 million, a significant increase from $269.4 million in the same period of 2009.
- 7The company's cash and investments position strengthened considerably, ending Q3 2010 at $1,620.6 million, up from $1,172 million at year-end 2009.